220 related articles for article (PubMed ID: 25285531)
1. A multicenter phase I/II study of obatoclax mesylate administered as a 3- or 24-hour infusion in older patients with previously untreated acute myeloid leukemia.
Schimmer AD; Raza A; Carter TH; Claxton D; Erba H; DeAngelo DJ; Tallman MS; Goard C; Borthakur G
PLoS One; 2014; 9(10):e108694. PubMed ID: 25285531
[TBL] [Abstract][Full Text] [Related]
2. A phase I study of obatoclax mesylate, a Bcl-2 antagonist, plus topotecan in solid tumor malignancies.
Paik PK; Rudin CM; Brown A; Rizvi NA; Takebe N; Travis W; James L; Ginsberg MS; Juergens R; Markus S; Tyson L; Subzwari S; Kris MG; Krug LM
Cancer Chemother Pharmacol; 2010 Nov; 66(6):1079-85. PubMed ID: 20165849
[TBL] [Abstract][Full Text] [Related]
3. Phase I study of obatoclax mesylate (GX15-070), a small molecule pan-Bcl-2 family antagonist, in patients with advanced chronic lymphocytic leukemia.
O'Brien SM; Claxton DF; Crump M; Faderl S; Kipps T; Keating MJ; Viallet J; Cheson BD
Blood; 2009 Jan; 113(2):299-305. PubMed ID: 18931344
[TBL] [Abstract][Full Text] [Related]
4. A phase I trial of pan-Bcl-2 antagonist obatoclax administered as a 3-h or a 24-h infusion in combination with carboplatin and etoposide in patients with extensive-stage small cell lung cancer.
Chiappori AA; Schreeder MT; Moezi MM; Stephenson JJ; Blakely J; Salgia R; Chu QS; Ross HJ; Subramaniam DS; Schnyder J; Berger MS
Br J Cancer; 2012 Feb; 106(5):839-45. PubMed ID: 22333598
[TBL] [Abstract][Full Text] [Related]
5. Phase I dose finding studies of obatoclax (GX15-070), a small molecule pan-BCL-2 family antagonist, in patients with advanced solid tumors or lymphoma.
Hwang JJ; Kuruvilla J; Mendelson D; Pishvaian MJ; Deeken JF; Siu LL; Berger MS; Viallet J; Marshall JL
Clin Cancer Res; 2010 Aug; 16(15):4038-45. PubMed ID: 20538761
[TBL] [Abstract][Full Text] [Related]
6. Obatoclax mesylate, a pan-bcl-2 inhibitor, in combination with docetaxel in a phase 1/2 trial in relapsed non-small-cell lung cancer.
Chiappori A; Williams C; Northfelt DW; Adams JW; Malik S; Edelman MJ; Rosen P; Van Echo DA; Berger MS; Haura EB
J Thorac Oncol; 2014 Jan; 9(1):121-5. PubMed ID: 24346101
[TBL] [Abstract][Full Text] [Related]
7. Phase 1/2 study of DFP-10917 administered by continuous intravenous infusion in patients with recurrent or refractory acute myeloid leukemia.
Kantarjian HM; Jabbour EJ; Garcia-Manero G; Kadia TM; DiNardo CD; Daver NG; Borthakur G; Jain N; Waukau JB; Kwari MI; Ravandi F; Anderson BD; Iizuka K; Jin C; Zhang C; Plunkett WK
Cancer; 2019 May; 125(10):1665-1673. PubMed ID: 30668890
[TBL] [Abstract][Full Text] [Related]
8. Clofarabine in combination with a standard remission induction regimen (cytosine arabinoside and idarubicin) in patients with previously untreated intermediate and bad-risk acute myelogenous leukemia (AML) or high-risk myelodysplastic syndrome (HR-MDS): phase I results of an ongoing phase I/II study of the leukemia groups of EORTC and GIMEMA (EORTC GIMEMA 06061/AML-14A trial).
Willemze R; Suciu S; Muus P; Halkes CJ; Meloni G; Meert L; Karrasch M; Rapion J; Vignetti M; Amadori S; de Witte T; Marie JP
Ann Hematol; 2014 Jun; 93(6):965-75. PubMed ID: 24682421
[TBL] [Abstract][Full Text] [Related]
9. A phase I study of the pan bcl-2 family inhibitor obatoclax mesylate in patients with advanced hematologic malignancies.
Schimmer AD; O'Brien S; Kantarjian H; Brandwein J; Cheson BD; Minden MD; Yee K; Ravandi F; Giles F; Schuh A; Gupta V; Andreeff M; Koller C; Chang H; Kamel-Reid S; Berger M; Viallet J; Borthakur G
Clin Cancer Res; 2008 Dec; 14(24):8295-301. PubMed ID: 19088047
[TBL] [Abstract][Full Text] [Related]
10. Phase I clinical and pharmacokinetic evaluation of high-dose mitoxantrone in combination with cytarabine in patients with acute leukemia.
Feldman EJ; Alberts DS; Arlin Z; Ahmed T; Mittelman A; Baskind P; Peng YM; Baier M; Plezia P
J Clin Oncol; 1993 Oct; 11(10):2002-9. PubMed ID: 8410125
[TBL] [Abstract][Full Text] [Related]
11. Phase I study of cladribine, cytarabine (Ara-C), granulocyte colony stimulating factor (G-CSF) (CLAG Regimen) and simultaneous escalating doses of imatinib mesylate (Gleevec) in relapsed/refractory AML.
Walker AR; Komrokji RS; Ifthikharuddin J; Messina P; Mulford D; Becker M; Friedberg J; Oliva J; Phillips G; Liesveld JL; Abboud C
Leuk Res; 2008 Dec; 32(12):1830-6. PubMed ID: 18571721
[TBL] [Abstract][Full Text] [Related]
12. Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study.
DiNardo CD; Pratz KW; Letai A; Jonas BA; Wei AH; Thirman M; Arellano M; Frattini MG; Kantarjian H; Popovic R; Chyla B; Xu T; Dunbar M; Agarwal SK; Humerickhouse R; Mabry M; Potluri J; Konopleva M; Pollyea DA
Lancet Oncol; 2018 Feb; 19(2):216-228. PubMed ID: 29339097
[TBL] [Abstract][Full Text] [Related]
13. A phase II, multicenter, open-label study of obatoclax mesylate in patients with previously untreated myelodysplastic syndromes with anemia or thrombocytopenia.
Arellano ML; Borthakur G; Berger M; Luer J; Raza A
Clin Lymphoma Myeloma Leuk; 2014 Dec; 14(6):534-9. PubMed ID: 25052051
[TBL] [Abstract][Full Text] [Related]
14. Guadecitabine (SGI-110) in treatment-naive patients with acute myeloid leukaemia: phase 2 results from a multicentre, randomised, phase 1/2 trial.
Kantarjian HM; Roboz GJ; Kropf PL; Yee KWL; O'Connell CL; Tibes R; Walsh KJ; Podoltsev NA; Griffiths EA; Jabbour E; Garcia-Manero G; Rizzieri D; Stock W; Savona MR; Rosenblat TL; Berdeja JG; Ravandi F; Rock EP; Hao Y; Azab M; Issa JJ
Lancet Oncol; 2017 Oct; 18(10):1317-1326. PubMed ID: 28844816
[TBL] [Abstract][Full Text] [Related]
15. Phase II study of obatoclax mesylate (GX15-070), a small-molecule BCL-2 family antagonist, for patients with myelofibrosis.
Parikh SA; Kantarjian H; Schimmer A; Walsh W; Asatiani E; El-Shami K; Winton E; Verstovsek S
Clin Lymphoma Myeloma Leuk; 2010 Aug; 10(4):285-9. PubMed ID: 20709666
[TBL] [Abstract][Full Text] [Related]
16. First-in-man study of CPX-351: a liposomal carrier containing cytarabine and daunorubicin in a fixed 5:1 molar ratio for the treatment of relapsed and refractory acute myeloid leukemia.
Feldman EJ; Lancet JE; Kolitz JE; Ritchie EK; Roboz GJ; List AF; Allen SL; Asatiani E; Mayer LD; Swenson C; Louie AC
J Clin Oncol; 2011 Mar; 29(8):979-85. PubMed ID: 21282541
[TBL] [Abstract][Full Text] [Related]
17. A phase II study of obatoclax mesylate, a Bcl-2 antagonist, plus topotecan in relapsed small cell lung cancer.
Paik PK; Rudin CM; Pietanza MC; Brown A; Rizvi NA; Takebe N; Travis W; James L; Ginsberg MS; Juergens R; Markus S; Tyson L; Subzwari S; Kris MG; Krug LM
Lung Cancer; 2011 Dec; 74(3):481-5. PubMed ID: 21620511
[TBL] [Abstract][Full Text] [Related]
18. A phase 1 trial of vadastuximab talirine as monotherapy in patients with CD33-positive acute myeloid leukemia.
Stein EM; Walter RB; Erba HP; Fathi AT; Advani AS; Lancet JE; Ravandi F; Kovacsovics T; DeAngelo DJ; Bixby D; Faderl S; Jillella AP; Ho PA; O'Meara MM; Zhao B; Biddle-Snead C; Stein AS
Blood; 2018 Jan; 131(4):387-396. PubMed ID: 29196412
[TBL] [Abstract][Full Text] [Related]
19. Treatment with PF-04449913, an oral smoothened antagonist, in patients with myeloid malignancies: a phase 1 safety and pharmacokinetics study.
Martinelli G; Oehler VG; Papayannidis C; Courtney R; Shaik MN; Zhang X; O'Connell A; McLachlan KR; Zheng X; Radich J; Baccarani M; Kantarjian HM; Levin WJ; Cortes JE; Jamieson C
Lancet Haematol; 2015 Aug; 2(8):e339-46. PubMed ID: 26688487
[TBL] [Abstract][Full Text] [Related]
20. Phase Ib Study of Glasdegib, a Hedgehog Pathway Inhibitor, in Combination with Standard Chemotherapy in Patients with AML or High-Risk MDS.
Savona MR; Pollyea DA; Stock W; Oehler VG; Schroeder MA; Lancet J; McCloskey J; Kantarjian HM; Ma WW; Shaik MN; Laird AD; Zeremski M; O'Connell A; Chan G; Cortes JE
Clin Cancer Res; 2018 May; 24(10):2294-2303. PubMed ID: 29463550
[No Abstract] [Full Text] [Related]
[Next] [New Search]
